Novamab Overview
- Year Founded
-
2017
- Status
-
Private
- Employees
-
60
- Latest Deal Type
-
Series BB
- Latest Deal Amount
-
$43.7M
- Investors
-
18
Novamab General Information
Description
Developer of a nano-antibody pharmaceutical designed to advance therapeutic development for oncology, autoimmune, and cardiovascular diseases. The company offers nano-antibody drug discovery and disease-focused research capabilities, enabling pharmaceutical companies and healthcare professionals in oncology, autoimmune, and cardiovascular fields to improve treatment outcomes for patients.
Contact Information
Website
www.novamab.comCorporate Office
- Building 10, Lane 500, Furonghua Road
- Pudong New Area
- Shanghai, 201318
- China
Corporate Office
- Building 10, Lane 500, Furonghua Road
- Pudong New Area
- Shanghai, 201318
- China
Novamab Timeline
Novamab Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 10. Later Stage VC (Series BB) | 17-Apr-2026 | $43.7M | Completed | Generating Revenue | ||
| 9. Later Stage VC (Series B3) | 10-Feb-2026 | Completed | Generating Revenue | |||
| 8. Later Stage VC (Series B2) | 20-Mar-2024 | Completed | Generating Revenue | |||
| 7. Later Stage VC (Series B1) | 15-Dec-2023 | Completed | Generating Revenue | |||
| 6. Early Stage VC | 14-Oct-2022 | Completed | Clinical Trials - Phase 1 | |||
| 5. Early Stage VC | 13-Jun-2022 | Completed | Clinical Trials - Phase 1 | |||
| 4. Early Stage VC (Series A1) | 08-Apr-2021 | Completed | Clinical Trials - Phase 1 | |||
| 3. Early Stage VC (Series A) | 12-Mar-2021 | Completed | Clinical Trials - Phase 1 | |||
| 2. Seed Round | 19-Jan-2018 | $4.44M | Completed | Startup | ||
| 1. Seed Round | 01-Aug-2017 | $4.44M | $4.44M | Completed | Startup |
Novamab Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Novamab Patents
Novamab Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026227267-A1 | Il-23 binding molecule and use thereof | Pending | 28-Apr-2025 | ||
| WO-2026183744-A1 | St2-targeting single-domain antibody and use thereof | Pending | 05-Mar-2025 | ||
| WO-2026086930-A1 | Tl1a binding molecule and use thereof | Pending | 25-Oct-2024 | ||
| WO-2026085874-A1 | Tl1a-binding molecule and use thereof | Pending | 25-Oct-2024 | ||
| WO-2026085716-A1 | New il-18 substitute and use thereof | Pending | 22-Oct-2024 |
Novamab Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Novamab Investors (18)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Guangdong Technology Financial Group | Government | Minority | ||
| Leading Capital Company | Asset Manager | Minority | ||
| Jinhe Capital | Growth/Expansion | Minority | ||
| Shenzhen Rurisheng Equity Investment | Growth/Expansion | Minority | ||
| Huangpu Biomedical Industry Investment Fund | Growth/Expansion | Minority |
Novamab FAQs
-
When was Novamab founded?
Novamab was founded in 2017.
-
Where is Novamab headquartered?
Novamab is headquartered in Shanghai, China.
-
What is the size of Novamab?
Novamab has 60 total employees.
-
What industry is Novamab in?
Novamab’s primary industry is Drug Discovery.
-
Is Novamab a private or public company?
Novamab is a Private company.
-
What is Novamab’s current revenue?
The current revenue for Novamab is .
-
How much funding has Novamab raised over time?
Novamab has raised $130M.
-
Who are Novamab’s investors?
Guangdong Technology Financial Group, Leading Capital Company, Jinhe Capital, Shenzhen Rurisheng Equity Investment, and Huangpu Biomedical Industry Investment Fund are 5 of 18 investors who have invested in Novamab.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
